Cancer Therapy-Induced Left Ventricular Dysfunction: Interventions and Prognosis

Abstract Background For multiple chemotherapeutics, cardiotoxicity is dose limiting and can lead to substantial morbidity and mortality. Early cardiac intervention has the potential to positively affect clinical course. Methods and Results We reviewed 247 consecutive patients referred to the Stanfor...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiac failure 2014-03, Vol.20 (3), p.155-158
Main Authors: Thakur, Akanksha, MD, Witteles, Ronald M., MD
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Agents - adverse effects
cardiomyopathy
Cardiotoxicity
Cardiovascular
Cardiovascular Agents - therapeutic use
chemotherapy
Cohort Studies
Early Medical Intervention - methods
Female
Humans
Male
Middle Aged
Neoplasms - diagnosis
Neoplasms - drug therapy
Prognosis
Retrospective Studies
Ventricular Dysfunction, Left - chemically induced
Ventricular Dysfunction, Left - diagnosis
Ventricular Dysfunction, Left - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background For multiple chemotherapeutics, cardiotoxicity is dose limiting and can lead to substantial morbidity and mortality. Early cardiac intervention has the potential to positively affect clinical course. Methods and Results We reviewed 247 consecutive patients referred to the Stanford cardiology clinic for cancer therapy-associated cardiac abnormalities from 2004 to 2012. A comprehensive review of records was performed, with documentation of baseline characteristics, cardiac imaging, medications, and clinical course. Seventy-nine patients who had left ventricular ejection fraction (LVEF) declines temporally associated with cancer therapy were included. The most common malignancies were breast (46%) and hematologic (35%); 71% of the patients were female, and overall mean age was 52 years. The primary cancer therapeutics associated with LVEF decline included anthracyclines, trastuzumab, and tyrosine kinase inhibitors. The mean LVEF was 60% before cancer therapy and 40% after cancer therapy. The most common cardiac interventions included beta-blockers (84%) and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (83%). Mean LVEF after cardiac intervention rose to 53%; 77% of patients had LVEF recovery to ≥50%, and 68% of these patients had recovery within 6 months of starting cardiac therapy; 76% of patients were able to continue their planned cancer therapy. Conclusions With appropriate cardiac intervention, the majority of patients with LVEF decline from cancer therapy can achieve LVEF recovery and complete their cancer therapy.
ISSN:1071-9164
1532-8414
DOI:10.1016/j.cardfail.2013.12.018